Ovid Therapeutics Inc.

NASDAQ:OVID

Biotechnology

Healthcare
$2.26 -4.34%

-$0.11 today

Market cap
$426.53M
Beta
0.18
P/E (TTM)
-7.1
EPS (TTM)
-$0.33
52W Low $0.29High $3.11

Volume 2.16M

Average 3.07M

OVID Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Ovid Therapeutics Inc.NASDAQ: OVID

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) grows in line with its trailing trend

Q1 FY2026 weighted avg shares (diluted) of 73.74M shares rose 3.8% year over year, behind the +4.7% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it fell 9.7% from the prior quarter. Over 3 fiscal years it compounded at +1.5% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +3.8% toward the trailing-twelve-month pace of +4.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
73.74M-9.7% QoQ
Last fiscal yearDec 2025
73.74M+4.0% YoY
LTMMar 2026
74.41M+4.7% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+3.8%——
1 year+4.0%——
3-year CAGR+1.5%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
73.74M USD
Year-over-year change
+4.0%
4-year CAGR
+2.0%

Weighted Avg Shares (Diluted) vs competitors

How OVID compares with its peers on the latest reported figures

  • OVID's LTM Mar 2026 weighted avg shares (diluted) of 74.41M shares is the 6th highest of the 11 companies compared; the peer median is 73.26M shares.
  • Its year-over-year change of +4.7% is the 9th highest of 11, against a peer median of +14.2%.
  • Over three fiscal years its annual growth of +1.5% compares with a peer median of +19.7%.
OVID Competitors Peer median
Weighted Avg Shares (Diluted) for OVID and competitors
Company Period LTM YoY 3-year CAGR
TSHATaysha Gene Therapies, Inc.LTM Jun 2026352.17M +35.4%+93.8%
WVEWave Life Sciences Ltd.LTM Mar 2026178.01M +19.3%+28.8%
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026111.46M +12.7%+17.7%
RAREUltragenyx Pharmaceutical Inc.LTM Mar 202699.68M +6.6%+12.1%
MGTXMeiraGTx Holdings plcLTM Mar 202680.99M +13.7%+21.2%
OVIDOvid Therapeutics Inc.LTM Mar 202674.41M +4.7%+1.5%
LXEOLexeo Therapeutics, Inc. Common StockLTM Mar 202665.52M +98.2%+28.7%
ABEOAbeona Therapeutics Inc.LTM Mar 202660.91M +28.1%+103.4%
STOKStoke Therapeutics, Inc.LTM Mar 202659.6M +4.3%+15.0%
VYGRVoyager Therapeutics, Inc.LTM Mar 202658.91M +1.6%+15.2%
NGNENeurogene Inc.LTM Mar 202620M +14.7%+18.2%
Peer median (excluding OVID) 73.26M+14.2%+19.7%

Competitors are the stored peer set for OVID. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue208.38M1.5M392K566K7.25M
Cost of Revenue0000300K
Gross Profit208.38M1.5M392K566K6.95M
Gross Margin100.0%100.0%100.0%100.0%95.9%
Research & Development46.94M24.62M28.59M36.77M25.58M
Selling, General & Admin37.23M32.43M29.59M25.68M24.11M
Operating Expenses84.17M57.05M59.67M62.45M49.39M
Depreciation & Amortization237.08K1.38M568K613K300K
EBITDA124.45M(54.17M)(57.01M)(57.77M)(17.11M)
EBITDA Margin59.7%-3604.5%-14544.1%-10207.1%-236.0%
Operating Income124.21M(55.55M)(59.28M)(61.89M)(42.44M)
Operating Margin59.6%-3696.4%-15122.7%-10933.7%-585.2%
Interest Income004.9M3.9M0
Interest Expense00000
Other Income / Expenses(45.69K)1.38M6.94M35.45M25.03M
Income Before Tax124.16M(54.17M)(52.34M)(26.43M)(17.41M)
Pre-Tax Margin59.6%-3604.7%-13351.8%-4670.1%-240.1%
Income Tax Expense1.33M0000
Net Income122.83M(54.17M)(52.34M)(26.43M)(17.41M)
Net Margin58.9%-3604.7%-13351.8%-4670.1%-240.1%
EPS (Basic)1.78(0.77)(0.74)(0.37)(0.24)
EPS (Diluted)1.76(0.77)(0.74)(0.37)(0.24)
Weighted Avg Shares67.48M70.43M70.58M70.91M73.74M
Weighted Avg Shares (Diluted)68.07M70.43M70.58M70.91M73.74M

Ovid Therapeutics Inc.

NASDAQ:OVID

Intrinsic Alpha fair value

Locked

Current Price

$2.26

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.